TNFRSF12A and cancer: As mentioned, TWEAK- or Fn14-targeting agents are already been used to inhibit the progression of tumors and have achieved some success in clinical and pre-clinical trials including a humanized antibody anti-TWEAK receptor is in phase 1 safety study in patients with solid tumors [11] and TWEAK and Fn14-targeting agents have already been tested in pre-clinical trials to treat cancer showing encouraging outcomes [6].